Abstract
Immunosuppressive drugs are widely used to treat undesirable immune reaction, however their clinical use is often limited by harmful side effects. The combined application of immunosuppressive agents with mesenchymal stem cells (MSCs) offers a promising alternative approach that enables the reduction of immunosuppressive agent doses and simultaneously maintains or improves the outcome of therapy. The present study aimed to determinate the effects of immunosuppressants on individual T cell subpopulations and to investigate the efficacy of MSC-based treatment combined with immunosuppressive drugs. We tested the effect of five widely used immunosuppressants with different action mechanisms: cyclosporine A, mycophenolate mofetil, rapamycin, and two glucocorticoids - prednisone and dexamethasone in combination with MSCs on mouse CD4+ and CD8+ lymphocyte viability and activation, Th17 (RORγt+), Th1 (T-bet+), Th2 (GATA-3+) and Treg (Foxp3+) cell proportion and on the production of corresponding key cytokines (IL-17, IFNγ, IL-4 and IL-10). We showed that MSCs modulate the actions of immunosuppressants and in combination with immunosuppressive drugs display distinct effect on cell activation and balance among different T lymphocytes subpopulations and exert a suppressive effect on proinflammatory T cell subsets while promoting the functions of anti-inflammatory Treg lymphocytes. The results indicated that MSC-based therapy could be a powerful strategy to attenuate the negative effects of immunosuppressive drugs on the immune system.
Similar content being viewed by others
References
Dobbels, F., Moons, P., Abraham, I., et al. (2008). Measuring symptom experience of side-effects of immunosuppressive drugs: the modified tranplant symptom occurrence and distress scale. Transplant International, 21, 764–773.
Hoogduijn, M. J., Crop, M. J., Peeters, A. M. A., et al. (2007). Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells and Development, 16, 597–604.
Kern, S., Eichler, H., Stoeve, J., Klueter, H., & Bieback, K. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24, 1294–1301.
Kong, Q.-F., Sun, B., Bai, S., et al. (2009). Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. Journal of Neuroimmunology, 207, 83–91.
Svobodova, E., Krulova, M., Zajicova, A., et al. (2012). The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells and Development, 21, 901–910.
Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815–1822.
Haynesworth, S. E., Baber, M. A., & Caplan, A. I. (1996). Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. Journal of Cellular Physiology, 166, 585–592.
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proceedings of the National Academy of Sciences of the United States of America, 99, 8932–8937.
Javorkova, E., Trosan, P., Zajicova, A., Krulova, M., Hajkova, M., & Holan, V. (2014). Modulation of the early inflammatory microenvironment in the alkali-burned eye by systemically administered interferon-gamma-treated mesenchymal stromal cells. Stem Cells and Development, 23, 2490–2500.
Gu, Y., Xue, Q., Chen, Y.-J., et al. (2013). Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Human Immunology, 74, 267–276.
Kim, S.-Y., Lee, J.-H., Kim, H. J., et al. (2012). Mesenchymal stem cell-conditioned media recovers lung fibroblasts from cigarette smoke-induced damage. American Journal of Physiology—Lung Cellular and Molecular Physiology, 302, L891–L908.
Ciccocioppo, R., Bernardo, M. E., Sgarella, A., et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut, 60, 788–798.
Casiraghi, F., Azzollini, N., Cassis, P., et al. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. Journal of Immunology, 181, 3933–3946.
Cejkova, J., Trosan, P., Cejka, C., et al. (2013). Suppression of alkali-induced oxidative injury in the cornea by mesenchymal stem cells growing on nanofiber scaffolds and transferred onto the damaged corneal surface. Experimental Eye Research, 116, 312–323.
Buron, F., Perrin, H., Malcus, C., et al. (2009). Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplantation Proceedings, 41, 3347–3352.
Hoogduijn, M. J., Crop, M. J., Korevaar, S. S., et al. (2008). Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation, 86, 1283–1291.
Chen, T. L., Wang, J. A., Shi, H., et al. (2008). Cyclosporin A pre-incubation attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Scandinavian Journal of Clinical & Laboratory Investigation, 68, 585–593.
Popp, F. C., Eggenhofer, E., Renner, P., et al. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transplant Immunology, 20, 55–60.
Eggenhofer, E., Renner, P., Soeder, Y., et al. (2011). Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transplant Immunology, 25, 141–147.
Ge, W., Jiang, J., Baroja, M. L., et al. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. American Journal of Transplantation, 9, 1760–1772.
Wang, H., Qi, F., Dai, X., et al. (2014). Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transplant Immunology, 31, 65–74.
Hajkova, M., Javorkova, J., Zajicova, A., et al. (2015). A local application of mesenchymal stem cells and cyclosporine A attenuates immune response by a switch in a macrophage phenotype. Journal of Tissue Engineering and Regenerative Medicine. doi:10.1002/term.2044.
Li, J.-F., Zhang, D.-J., Geng, T., et al. (2014). The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplantation, 23, S113–S122.
Peng, Y., Ke, M., Xu, L., et al. (2013). Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation, 95, 161–168.
Perico, N., Casiraghi, F., Introna, M., et al. (2011). Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clinical Journal of the American Society of Nephrology, 6, 412–422.
Fanigliulo, D., Lazzerini, P. E., Capecchi, P. L., Ulivieri, C., Baldari, C. T., & Laghi-Pasini, F. (2015). Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in healthy humans. International Immunopharmacology, 24, 276–284.
Kawabe, Y., & Ochi, A. (1991). Programmed cell death and extrathymic reduction of Vβ8+CD4+ T-cells in mice tolerant to Staphylococcus aureus enterotoxin. Nature, 349, 245–248.
Crowe, S. M., Carlin, J. B., Stewart, K. I., Lucas, C. R., & Hoy, J. F. (1991). Predictive value of lymphocyte-CD4 numbers for the devlopment of oportunistic infections and malignancies in HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 4, 770–776.
Xu, G., Zhang, Y., Zhang, L., Ren, G., & Shi, Y. (2007). The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochemical and Biophysical Research Communications, 361, 745–750.
Benvenuto, F., Ferrari, S., Gerdoni, E., et al. (2007). Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells, 25, 1753–1760.
Normanton, M., Alvarenga, H., Hamerschlak, N., et al. (2014). Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion. PloS One, 9, e106673.
Le Blanc, K., Rasmusson, I., Gotherstrom, C., et al. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scandinavian Journal of Immunology, 60, 307–315.
Talaat, R. M., Mohamed, S. F., Bassyouni, I. H., & Raouf, A. A. (2015). Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine, 72, 146–153.
Ma, L., Zhang, H. M., Hu, K. B., et al. (2015). The imbalance between Tregs, Th17 cells and inflammatory cytokines among renal transplant recipients. BMC Immunology, 16. doi:10.1186/s12865-015-0118-8.
Mohammadzadeh, A., Pourfathollah, A. A., Shahrokhi, S., Hashemi, S. M., Moradi, S. L. A., & Soleimani, M. (2014). Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. International Immunopharmacology, 20, 316–321.
Prado, C., de Paz, B., Gomez, J., Lopez, P., Rodriguez-Carrio, J., & Suarez, A. (2011). Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients. Rheumatology, 50, 1794–1801.
Abadja, F., Atemkeng, S., Alamartine, E., Berthoux, F., & Mariat, C. (2011). Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation, 92, 396–403.
Weigel, G., Griesmacher, A., Karimi, A., Zuckermann, A. O., Grimm, M., & Mueller, M. M. (2002). Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. Journal of Heart and Lung Transplantation, 21, 1074–1079.
Chang, J. W., Hung, S. P., Wu, H. H., et al. (2011). Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplantation, 20, 245–257.
Goodwin, M., Sueblinvong, V., Eisenhauer, P., et al. (2011). Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells, 29, 1137–1148.
Miroux, C., Morales, O., Ouaguia, L., et al. (2012). Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil. Transplantation Proceedings, 44, 2834–2839.
Rovira, J., Renner, P., Sabet-Baktach, M., et al. (2016). Cyclosporine A inhibits the T-bet-dependent antitumor response of CD8+ T cells. American Journal of Transplantation, 16, 1139–1147.
Lemaitre, P. H., Vokaer, B., Charbonnier, L. M., et al. (2013). Cyclosporine A drives a Th17-and Th2-mediated posttransplant obliterative airway disease. American Journal of Transplantation, 13, 611–620.
Acknowledgements
This study was supported by grant 80815 from the Grant Agency of Charles University, the grant 14-12580S, and by the projects SVV 260310, UNCE 204013, NPU-I:LO1508 and NPU-I: LO1309 and P41-20504151.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Hajkova, M., Hermankova, B., Javorkova, E. et al. Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations. Stem Cell Rev and Rep 13, 104–115 (2017). https://doi.org/10.1007/s12015-016-9703-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-016-9703-3